Skip to main content

Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma.

Publication ,  Journal Article
DuBois, SG; Messina, J; Maris, JM; Huberty, J; Glidden, DV; Veatch, J; Charron, M; Hawkins, R; Matthay, KK
Published in: J Clin Oncol
June 15, 2004

PURPOSE: Iodine-131-metaiodobenzylguanidine ((131)I-MIBG) has been shown to be active against refractory neuroblastoma. The primary toxicity of (131)I-MIBG is myelosuppression, which might necessitate autologous hematopoietic stem-cell transplantation (AHSCT). The goal of this study was to determine risk factors for myelosuppression and the need for AHSCT after (131)I-MIBG treatment. PATIENTS AND METHODS: Fifty-three patients with refractory or relapsed neuroblastoma were treated with 18 mCi/kg (131)I-MIBG on a phase I/II protocol. The median whole-body radiation dose was 2.92 Gy. RESULTS: Almost all patients required at least one platelet (96%) or red cell (91%) transfusion and most patients (79%) developed neutropenia (< 0.5 x 10(3)/microL). Patients reached platelet nadir earlier than neutrophil nadir (P <.0001). Earlier platelet nadir correlated with bone marrow tumor, more extensive bone involvement, higher whole-body radiation dose, and longer time from diagnosis to (131)I-MIBG therapy (P

Duke Scholars

Published In

J Clin Oncol

DOI

ISSN

0732-183X

Publication Date

June 15, 2004

Volume

22

Issue

12

Start / End Page

2452 / 2460

Location

United States

Related Subject Headings

  • Transplantation, Autologous
  • Thrombocytopenia
  • Radiopharmaceuticals
  • Oncology & Carcinogenesis
  • Neutropenia
  • Neuroblastoma
  • Male
  • Iodine Radioisotopes
  • Infant
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
DuBois, S. G., Messina, J., Maris, J. M., Huberty, J., Glidden, D. V., Veatch, J., … Matthay, K. K. (2004). Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma. J Clin Oncol, 22(12), 2452–2460. https://doi.org/10.1200/JCO.2004.08.058
DuBois, Steven G., Julia Messina, John M. Maris, John Huberty, David V. Glidden, Janet Veatch, Martin Charron, Randall Hawkins, and Katherine K. Matthay. “Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma.J Clin Oncol 22, no. 12 (June 15, 2004): 2452–60. https://doi.org/10.1200/JCO.2004.08.058.
DuBois SG, Messina J, Maris JM, Huberty J, Glidden DV, Veatch J, et al. Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma. J Clin Oncol. 2004 Jun 15;22(12):2452–60.
DuBois, Steven G., et al. “Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma.J Clin Oncol, vol. 22, no. 12, June 2004, pp. 2452–60. Pubmed, doi:10.1200/JCO.2004.08.058.
DuBois SG, Messina J, Maris JM, Huberty J, Glidden DV, Veatch J, Charron M, Hawkins R, Matthay KK. Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma. J Clin Oncol. 2004 Jun 15;22(12):2452–2460.

Published In

J Clin Oncol

DOI

ISSN

0732-183X

Publication Date

June 15, 2004

Volume

22

Issue

12

Start / End Page

2452 / 2460

Location

United States

Related Subject Headings

  • Transplantation, Autologous
  • Thrombocytopenia
  • Radiopharmaceuticals
  • Oncology & Carcinogenesis
  • Neutropenia
  • Neuroblastoma
  • Male
  • Iodine Radioisotopes
  • Infant
  • Humans